Introduction {#sec1-1}
============

*Candida* and *Aspergillus* spp. are mainly the causes of invasive fungal infections in hospitals. However, infection with rare fungal pathogens has become more popular in recent years. Infections caused by *Saprochaete capitata* are one of the emerging diseases. *S. capitata*, previously known as *Geotrichum capitatum, Trichosporon capitatum, Blastoschizomyces capitatus, Dipodascus capitatus*, is a non-fermentative, urease-negative ascomycetous yeast classified in Saccharomycetaceae family \[[@ref1]\], \[[@ref2]\], \[[@ref3]\], \[[@ref4]\], \[[@ref5]\], \[[@ref6]\], \[[@ref7]\]. *S. capitata* fungus grows well in the Saboraud agar, their colonies are similar to yeast, but their morphology characterizes with long and short segments with different sizes. This fungus is mainly found in natural environments such as soil, sand and wood pulp \[[@ref8]\]. In addition, it has also been found in poultry feces, gastrointestinal tract, respiratory tract, and is a part of the normal microflora of human skin \[[@ref9]\]. They are known as the fungi that live in the respiratory tract and digestive tracts of humans, they are invasive pathogens like other yeast species \[[@ref10]\].

*S. capitata* infection is mainly seen in patients with neutrophil leukemia (87%), more rarely in patients with other non-hematological diseases such as diabetes, neuralgia, organ transplantation and inflammations \[[@ref11]\] ([Table 1](#T1){ref-type="table"}). In this report, we described a case of fungal infection caused by *S. capitata* in COPD patients.

###### 

Some report cases cause by *Saprochaete capitata*

  No.   Case                     Age   Symptoms/ problems                                  Treatment                                  References
  ----- ------------------------ ----- --------------------------------------------------- ------------------------------------------ --------------
  1     Acute myeloid leukemia   41    Erythema, high fever                                caspofungin and liposomal amphotericin B   \[[@ref12]\]
  2     Kidney transplant        82    hypertensive nephrosclerosis                        liposomal amphotericin B                   \[[@ref13]\]
  3     Burkitt lymphoma         74    fever and central nervous system                    fluconazole and caspofungin                \[[@ref12]\]
  4     Acute myeloid leukemia   57    Fever, diarrhoea and skin rash                      levofloxacin fluconazole                   \[[@ref14]\]
  5     Pneumonia, asthama       86    shortness of breath, productive cough and fatigue   itraconazole                               \[[@ref15]\]

Clinical Case {#sec1-2}
=============

An 80-year-old man was diagnosed with COPD and Gout 10 years ago. The patient came to the hospital with productive cough, dyspnea, chest pain on both sides a week before. Examination revealed symptoms including vesicular breathing, coarse crackle and wheeze in both lungs, no hypertension, non-diabetic, no fever. The laboratory blood test results were: Red blood cell 4.36 T/L, hematocrit 138 g/l, White blood cell 12.8 G/L (Lymphocyte 17.4% and Granulocyte 74.1%), HIV negative, Genxpert DPG (-), AFB (-). The X-ray showed bronchitis and emphysema. Bronchoscopy illustrated bronchial mucositis ([Figure 1](#F1){ref-type="fig"}).

![X -- ray of patient before treatment](OAMJMS-7-4329-g001){#F1}

CT scanner demonstrated the pneumonia with fuzzy nodular lesions and thick interstitial organization in both lungs ([Figure 2](#F2){ref-type="fig"}). The patient was treated with ciprofloxacin 800mmg/day; cefuroxime 2250 mmg/day; ventolin 40mg/ day; pulmicort 500mg; salbutamol 16mg/ day.

![CT scan of the patient before treatment](OAMJMS-7-4329-g002){#F2}

After 2 weeks, cough and shortness of breath decreased, fever, however, developed. The patient was then treated with methylprednisolon 40 mg per day for 7 days. After the cease of drug, fever again developed. Therefore, the patient was treated with raxadin 2000 mmg + moxifloxacin 400 mmg + doxycyclin 1000 mmg per day for another 7 days. The patient was still feverish, tired, screeching and snoring was in both sides of the lung. The phlegm of patient was sampled and cultured to find fungi. *S. capitate* was detected by semi-automatic Vitek system ([Figure 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}), the blood cultured showed negative.

![Saprochaete capitata on SAB media at 72 hour at 37°C](OAMJMS-7-4329-g003){#F3}

![Saprochaete capitata staining with lactophenol cotton blue under microscope (X 400)](OAMJMS-7-4329-g004){#F4}

After 14 days of treatment with fluconazol 400 mg per day, the patient recovered and all the symptoms disappeared. The phlegm cultured showed negative.

Discussion {#sec1-3}
==========

*Saprochaete capitata* has determined considerable taxonomic evaluation \[[@ref16]\]. Evaluation of this fungus under microscopy showed the septal pores and cell wall structurewith lots of arthroconidia and few blastoconidia \[[@ref1]\]. In our case, *S. capitata* grow well on the Saboraud agar at 37°C, the colonies are similar to those of yeast. However, it is, with different dimensions of segments under microscope ([Figure 4](#F4){ref-type="fig"}), similar to the filamentous fungi. Conventionally, detection of these fungi in the culture medium basing on their morphology is an important diagnosis. Using automatic or semi-automatic system may be a great choice. The Vitek 2 system version 07.01 was used to confirm *S. capitata*. This system has been shown to possess an accuracy rate of 98%. Besides, D 32C (bioMérieux), and RapID Yeast Plus (Innovative Diagnostic Systems) systems also were applied to diagnosis of this fungus \[[@ref17]\], \[[@ref18]\]. Unfortunately, their mophology is very similar to that of *S. clavata* \[[@ref17]\].

*S. capitata* infection is becoming an emerging disease, particularly in immunocompromised such as haematological malignancies, asscociated cancer and onychomycosis \[[@ref19]\]. Factors such as extended neutropenia, active chemotherapy, broad-spectrum antibiotics use and reduced local defense system by breaking down the skin and mucosa were mainly beneficial factors for this infection \[[@ref20]\]. The haematological malignancy including acute leukemia is the disease in the most popular patients and estimated incidence is around 0.5% \[[@ref1]\], \[[@ref21]\]. Extremely, all of breaking through infections with acute leukemia developed in patients who were in intentive chemotherapy \[[@ref1]\]. Moreover, broad spectrum antibiotic was used for treatment of all patients who developed neutropenic fever. The 30-day mortality is 30 days it related with invasive disease ranges from 60 -- 80% \[[@ref1]\]. In this case, the patient was treated with two antibioticsfor 14 days. The symptoms decrease at the end of antibiotic treatment. However, the patient appeared fever in the afternoon. This case indicates the antibiotics ciprofloxacin and cefuroxime are not really effective with S. capitata. Positive blood culture was found in almost of case infection with 77.3%. While our case showed negative in blood culture. The pneumonia in S. capitata usually associated in haematological malignancies or multiple diseases. It could make the infection becomes more severse \[[@ref15]\].

The in vitro study of susceptibility *S. capitata* is quite weak. Published literature showed that *S. capitata* is susceptible to flucytosine (MIC values 0.25-0.5 mg/mL), itraconazole (MIC values 0.12-0.50 mg/mL), voriconazole (MIC values 0.25-0.5 mg/mL) and posaconazole (MIC values 0.03-0.25 mg/mL). However, these organisms are less susceptible to fluconazole with a MIC between 16 and 32 mg/mL in most studies \[[@ref3]\], \[[@ref22]\], \[[@ref23]\]. Amphotericin B was effective in inhibition of these fungus only with high concentration (MIC values 0.5-2.0 mg/mL) \[[@ref24]\]. *S. capitata* was demonstrated to intrinsically resist to echinocandins \[[@ref25]\]. Girmenia et al. reported that amphotericin B, flucytosine, fluconazole, itraconazole, and voriconazole hadhigh efficacy against *S. capitata* isolates. Other authors indicated that amphotericin B and voriconazole were more potent than other drugs in inhibition of *S. capitata* \[[@ref23]\]. In these cases, demonstrated *S. capitata* reduce susceptive to anidulafungin at 8 mg/mL MIC value as expected. Fluconazole is less effective than itraconazole, voriconazole and azoles against *S. capitata*. The data of optimal treatment to *S. capitata* infection is not enough. In this infection indicated use of amphotericin B alone or in combination with flucytosine is a quality treatment. *S. capitata* infection treat with fluconazole and echinocandins were also quite good choice. Breakthrough infections of *S. capitata* reported in neutropenic patients collected echinocandins \[[@ref7]\], \[[@ref26]\], \[[@ref27]\]. In our case, *S. capitata* was effectively treated with fluconazole 400 mg/day per 14 days, but it is need more evidence of MIC value. This case also demonstrates that antibiotic treatment of this infection only reduces some symptoms, but it is unable to thoroughly treat the infection. Identification of fungi is the most important for diagnosis and treatment.

In conclusion, *S. capitata* infected mostly to haematological malignancies patients, also with immunosuppressive and immunocompetent patients. In this case, the COPD patient was infected with *S. capitata*, treated with fluconazole 400 mg/day. The signs and symptoms disappeared after 2 weeks. The MIC of *S. capitata* should be do in the further study.
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